United
States head and neck cancer therapeutics market is expected to grow at an
impressive rate during the forecast period, 2024-2028 owing to the rising incidence
rates of head and neck cancer, technological advancements, focus on immunotherapy,
collaborative research efforts, increased awareness, and supportive regulatory
and reimbursement policies.
The
rising incidence of head and neck cancer in the United States is one of the
primary drivers fueling the market expansion. The increase in incidents has
been attributed to a number of causes due to tobacco use, excessive alcohol
consumption, human papillomavirus (HPV) infection, and exposure to specific
occupational hazards. Advanced therapies have been introduced as a result of
research and development efforts driven by the demand for efficient treatment
alternatives for combating the problem.
The
landscape of head and neck cancer therapeutics has gone through an
evolution due to developments in medical technology. New therapeutic options
have been made possible by the development of immunotherapies, targeted
treatments, and precision medicine techniques. Genomic and molecular tests
allow for the creation of personalized treatment programs for each patient,
increasing the overall effectiveness of therapeutics. Additionally,
improvements in radiation therapy and surgical methods have improved treatment
outcomes and decreased side effects, spurring the market expansion.
Proactive
programs for screening and increased awareness campaigns have assisted in
detecting head and neck cancer early. Early diagnosis allows prompt action,
which enhances the effectiveness of treatment. Additionally, campaigns to
educate the public have emphasized the significance of risk factor
modification, such as quitting smoking and drinking alcohol in moderation, to
lower the frequency of preventable instances. The demand for efficient
medicines has increased due to the focus on early detection and prevention.
The
field of head and neck cancer therapeutics is seeing a growing interest in
precision medicine, which involves modifying therapy regimens, based on a
patient's genetic profile. Medical professionals may identify precise genetic
changes and biomarkers that fuel tumor growth through developments in genomic
testing and molecular profiling tools. Tyrosine kinase inhibitors and
monoclonal antibodies, which specifically target cancer cells while minimizing
harm to healthy organs, can be developed as a result of this information.
Precision medicine's rising popularity is predicted to fuel the market by
enhancing treatment outcomes and lowering adverse effects.
The
field of head and neck cancer therapeutics may undergo a transformation due to
the integration of artificial intelligence (AI) and big data analytics. To identify
patterns, forecast treatment outcomes, and direct personalized treatment
decisions, artificial intelligence can analyze enormous volumes of patient
data, including medical records, imaging scans, and genomic profiles. This
data-driven strategy has the potential to improve treatment approaches and
advance precision medicine. The use of AI and big data analytics in clinical
settings will boost the market and enhance patient outcomes.
Patient-centered
care and supportive care services have become increasingly important in the
treatment of head and neck cancer. Supportive treatment concentrates on
treating complications of the drugs, enhancing patients' quality of life, and
offering psychosocial support. Incorporating palliative care services to cancer
therapy has been found to improve patient satisfaction and treatment
compliance. The demand for supportive care services will increase, supporting
market expansion as healthcare systems prioritize complete patient care.
There
are some challenges that are hampering the growth of United States head and
neck cancer therapeutics market. These challenges include high treatment costs,
limited options for rare subtypes, resistance to therapy, treatment-related
toxicities, regulatory hurdles, and limited awareness.
The
cost of treating cancer, including head and neck cancer, appears to be a major
issue. Targeted and immunotherapies are examples of novel medicines with
substantial price tags. The total costs of these therapies are affected by the
high cost of research and development, clinical trials, manufacturing, and
distribution.
Significant
side effects and toxicities can arise from the severe nature of head and neck
cancer treatment, which typically involves surgery, radiation therapy, and
chemotherapy. These might involve xerostomia, dysphagia, mucositis, and
long-term side effects including persistent pain and swallowing issues. These
side effects may have a significant negative influence on patients' functional
results and quality of life. To enhance patient experiences and treatment
adherence, efforts to minimize toxicities associated with the treatment must be
made for the development of supportive care techniques.
Growing
Incidences of Head and Neck Cancer
The
incidence of head and neck cancer is on the rise worldwide, including in the
United States, which is a major threat to public health. To improve treatment
outcomes and improve patient care, there has been a lot of research and
development due to the rise in cases. The expansion of the head and neck cancer
therapeutics market in the United States is influenced by the rising incidence of
head and neck cancer. ASCO estimates that 4% of all malignancies in the
United States are head and neck cancers. A projected 66,920 individuals (49,190
males and 17,730 women) will be diagnosed with a head and neck cancer in 2023.
The
prevalence of head and neck cancer is rising as a result of a number of
factors, including tobacco use, excessive alcohol consumption, human
papillomavirus (HPV) infection, and exposure to specific occupational dangers.
Pharmaceutical
companies and academic institutions are continually investigating fresh
medications and therapeutic approaches to treat head and neck cancer. A few of
these developments are precision medicine approaches, targeted drugs, and
immunotherapies that are customized to each patient's unique genetic profile
and tumor features.
Clinical
Trial Status
· On June 30, 2022, regardless of PD-L1 status,
Novartis announced findings from the Phase III RATIONALE 306 trial
demonstrating that tislelizumab plus chemotherapy significantly increased
overall survival (OS) as a first-line treatment for adult patients with
unresectable, locally advanced, or metastatic esophageal squamous cell
carcinoma (ESCC).
· Imfinzi (durvalumab) by AstraZeneca did not succeed
in improving overall survival (OS) compared to the EXTREME treatment plan
(chemotherapy plus cetuximab), the standard of care, in the KESTREL Phase III
trial. These patients had head and neck squamous cell carcinoma (HNSCC) which
was recurrent or metastatic and whose tumors had high levels of PD-L1. Additionally,
the addition of Imfinzi and tremelimumab did not work to show a benefit for OS
in 'all-comer' patients, a secondary goal.
· On December 7, 2018, AstraZeneca and MedImmune, its
worldwide biologics research and development company, released the Phase III
EAGLE trial's overall survival (OS) data. Regardless of the patients' PD-L1
tumor status, the EAGLE trial compares Imfinzi (durvalumab) monotherapy or
Imfinzi in combination with the anti-CTLA4 antibody tremelimumab to
standard-of-care (SoC) chemotherapy for patients with metastatic or recurrent
head and neck squamous cell carcinoma (HNSCC) who experienced disease
progression after platinum-based chemotherapy.
·
On March 13, 2020, Pfizer Inc. and EMD Serono, the
biopharmaceutical division of Merck KGaA, Darmstadt, Germany, in the US and
Canada, released an update from the Phase III JAVELIN Head and Neck 100 study
comparing the effectiveness of avelumab in addition to standard-of-care CRT
versus LA SCCHN patients who had not yet received treatment for their disease.
The alliance has agreed to the independent Data Monitoring Committee's (DMC)
recommendation to end the JAVELIN Head and Neck 100 trial because, according to
an anticipated interim analysis, the trial is not likely to demonstrate a
statistically significant improvement in the primary endpoint of
progression-free survival (PFS).
· Tecentriq® (atezolizumab) and Avastin®
(bevacizumab) demonstrated a statistically significant improvement in
recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC)
at high risk of disease recurrence after liver resection or ablation with
curative intent, according to new data from the Phase III IMbrave050 study.
FDA
Approvals
- Pembrolizumab (KEYTRUDA, Merck) was
given FDA approval on June 10, 2019, to be used as the first-line
treatment for people with metastatic or unresectable recurrent head and
neck squamous cell carcinoma (HNSCC). The FDA approved the use of
pembrolizumab as a single drug for patients whose tumors express PD-L1 (Combined
Positive Score [CPS]] 1 as determined by an FDA-approved test) and in
combination with platinum and fluorouracil (FU) for all patients.
Market Segmentation
The United
States head and neck cancer therapeutics market can be segmented by type,
disease indication, route of administration, therapeutic class, end user, and region. By type, the United States head
and neck cancer therapeutics market can be segmented into diagnostic methods and
treatment type. Based on diagnostic methods, the United States head and neck
cancer therapeutics market is divided into biopsy, imaging, endoscopy, and others.
Based on treatment type, the United States head and neck cancer therapeutics
market is divided into surgery, radiation therapy, chemotherapy, immunotherapy,
and targeted therapy. Based on disease indication, the United States head and
neck cancer therapeutics market is divided into lip and oral cavity cancer,
laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal
cancer, and hypopharyngeal cancer. Based on route of administration, the United
States head and neck cancer therapeutics market is divided into injectable and oral.
Based on therapeutic class, the United States head and neck cancer therapeutics
market is divided into PD inhibitors, EGFR inhibitors, and microtubule
inhibitors. Based on end user, the United States head and neck cancer
therapeutics market is segmented into hospitals, specialty clinics, ambulatory
surgical centers, and others.
Market Players
Merck & Co., Inc., Bristol
Myers Squibb, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc.,
Amgen Inc., AbbVie Inc., Novartis AG are some of the leading companies operating
in the market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
Type
Disease Indication
Route of Administration
Therapeutic Class
End User
|
|
Regional scope
|
Northeast Region; Midwest Region; South Region; West Region
|
|
Key companies profiled
|
Merck & Co., Inc., Bristol Myers
Squibb, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc.,
Amgen Inc., AbbVie Inc., Novartis AG
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United States head and
neck cancer therapeutics market has been segmented into following categories,
in addition to the industry trends which have also been detailed below:
- United States Head and Neck
Cancer Therapeutics Market, By Type
- Diagnostic Methods
- Treatment Type
- United States Head and Neck Cancer Therapeutics Market, By Disease
Indication
- Lip & Oral Cavity Cancer
- Laryngeal Cancer
- Oropharyngeal Cancer
- Salivary Gland Cancer
- Nasopharyngeal Cancer
- Hypopharyngeal Cancer
- United States Head and Neck Cancer Therapeutics Market, By Route
of Administration
- United States Head and Neck Cancer Therapeutics Market, By Therapeutic
Class
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- United States Head and Neck Cancer Therapeutics Market, By End
User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in United States head and neck cancer therapeutics
market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market
players (up to five).
It is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]